STAREE Trial: Atorvastatin Reduces Heart Attack Risk in Older Adults

The STAREE clinical trial found that Atorvastatin reduces major cardiovascular events by 30% in healthy adults over the age of 70.

The study, published on August 30, 2026, indicates that the benefit is primarily driven by a reduction in nonfatal heart attacks and strokes.

While the drug met its primary cardiovascular endpoint, it did not significantly impact disability-free survival goals in the elderly cohort.